•
Suzhou-based gene therapy specialist, Gritgen Therapeutics Co., Ltd, has announced the validation completion and initiation of operations at its commercial Good Manufacturing Practice (GMP) facilities located in the Suzhou Industrial Park. This development marks a significant step forward for the company in advancing its capabilities in gene therapy production. Facility…
•
Gritgen Therapeutics, a leading gene therapy drug developer based in Suzhou, has announced the successful completion of a A-round financing round worth several hundred million yuan. The financing was led by Sequoia China, with participation from Sunlight Insurance, Qingsong Capital, and Beijing Life Science Park Venture Fund. Existing shareholders including…